Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Thyrogen(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are registered trademarks of and Mozobil(TM) and Synvisc-ONE(TM) are unregistered trademarks of Genzyme or its subsidiaries. Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. All rights reserved.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

Conference Call Information

Genzyme will host a conference call today at 11:00 a.m. Eastern to discuss results for the first quarter of 2008. To participate in the call, please dial 773-799-3828 and refer to pass code "Genzyme." A replay of this call will be available by dialing 402-998-1342. This call will also be Webcast live on the investor events section of http://www.genzyme.com. Replays of the call and th
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic Biologics, ... developing novel anti-infective biologic and drug programs targeting ... announced today that its novel C. difficile ... 54 th Interscience Conference on Antimicrobial Agents ... Washington D.C. Synthetic Biologics, ...
(Date:8/18/2014)... (PRWEB) August 19, 2014 2014 ... Industryā€¯ is a professional and in-depth research report ... basic Linalool information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
(Date:8/18/2014)... August 18, 2014 Global HIV Infection ... report announced by Reportstack. The rate of HIV infection and ... a declining note at a positive rate across the globe. ... 2.3 million in 2005 to 1.5 in 2013, with the ... for such drastic changes in the infection rates has been ...
Breaking Biology Technology:Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... and preventive vaccines against cancers and infectious diseases, announced ... showed remarkable immune responses in monkeys, following similarly strong, ... data from earlier animal studies. The data was presented ...
... the term "splitsville" usually means "check your prenup." ... from boron nitride nanotubes, "splitsville" could mean "happily ... National Laboratory (Berkeley Lab) and the University of ... University, have developed a technique in which boron ...
... HAYWARD, Calif., June 28, 2011 Intarcia Therapeutics, ... results of a phase 2 clinical study of ... for the treatment of type 2 diabetes at ... San Diego, California. (Logo:   http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO ...
Cached Biology Technology:Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 2Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 3Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 4Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 5Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 6Splitsville for boron nitride nanotubes 2Splitsville for boron nitride nanotubes 3Splitsville for boron nitride nanotubes 4Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 2Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 3Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 4Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 5
(Date:8/19/2014)... the seas during warm phases and became extinct during ... establishes a link between marine crocodilian diversity and the ... than 140 million years. , The research, led ... France and formerly from the University of Bristol, UK ... Today, crocodiles are ,cold-blooded, animals that mainly live in ...
(Date:8/19/2014)... ever had a glass of fizzy soda knows that ... in a finding with wide industrial applications, Princeton researchers ... down into the liquid as well. , "It is ... we were surprised, and fascinated, to discover that when ... injected tiny oil droplets into the water," said Howard ...
(Date:8/19/2014)... Rochelle, August 19, 2014A new ovoid structure discovered in ... clay, contains a variety of minerals, and shows evidence ... resulting melting of the permafrost and mixing of surface ... broad range of analytical studies to determine the origin ... for how this ovoid formed, point to the most ...
Breaking Biology News(10 mins):Evolution of marine crocodilians constrained by ocean temperatures 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3Life on Mars? Implications of a newly discovered mineral-rich structure 2
... Doha, Qatar Urgent law enforcement action by governments ... crucial to addressing the illicit ivory trade, according to ... Detailed regional summaries of the data held in ... database on ivory seizures, highlight the failure of law ...
... ever before of how much radiation reaches sensitive tissues ... models of the human body being developed at the ... of computer simulation tools and 3-D patient models that ... said Wesley E. Bolch, Ph.D., a professor in the ...
... monster movies, but palaeontologists have discovered evidence of how an ... place 4 million years ago. Such fossil evidence ... of bite marks on an otherwise well-preserved dolphin skeleton, the ... that led to the death of the dolphin, and determined ...
Cached Biology News:New analysis points to ivory enforcement failures in parts of Africa, Asia 2Age, gender can affect risk to radiation treatment 2Age, gender can affect risk to radiation treatment 3Jaws -- 4 million BC 2
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Fluorescence Preserving Media, 100 mL...
... Blunt-Ended PCR Cloning Kit, 40 reactions. ... cloning of all PCR products with ... cloning approaches by offering consistently better ... 25-fold more positive clones.Amplicons generated by ...
... development to targets including proteins and to ... cancer-specific surface antigens. A&Gs service is ... in approximately 40 days (duration may vary ... Phase I: Immunization, test bleed and ...
Biology Products: